Brain tumours such as glioblastoma multiforme (GBM) remain difficult, if not impossible, to treat due to their location deep inside the brain, and their aggressive characteristics. Existing therapies offer only marginal increase in survival rates. Photomedical therapies, on the other hand, are limited by their insufficient depth of light penetration, Neutron-based therapies such as Neutron Boron Capture Therapy (NBCT), can provide sufficient penetration depth, but lack cancer specificity.
FRINGE proposes a genuinely new hybrid-technology concept, combining the efficiency of photomedical therapies with the advantages of neutron-based therapies (large penetration depth) to lay the foundation for a novel, curative cancer therapy. FRINGE can utilise already existing NBCT infrastructures, which are currently underused due to the lack of specificity of NBCT alone.
The main scientific breakthrough of this project will be to establish experimental proof-of-principle of this novel neutron-activated therapy, which requires the concerted action of conventionally non-interacting disciplines – synthetic chemistry, photochemistry, photobiology, photomedicine, computational chemistry, neutron physics and nuclear medicine.
Within the FET Open FRINGE Research and Innovation Action, accelopment leads Work Package 6, which is dedicated to the communication of the project to different stakeholder groups, and the dissemination and exploitation of its research results in order to maximise the impact of the project. Furthermore, accelopment chairs the Management Support Team as FRINGE’s Administrative Project Manager.